Facilities & Capacity

Gritgen validates China plant as it advances hemophilia A gene therapy

Suzhou Gritgen Therapeutics has opened a commercial gene therapy facility in Suzhou Industrial Park, China. Gritgen develops adeno associated virus (AAV) gene therapies, with its next-gen AAV capsid platform and efficient promotors and enhancers. The GMP facility is built to comply with global cGMP standards, including the NMPA, the FDA and the EMA. The 8,600 square-meter manufacturing facility will house plasmid production and AAV production lines. The production lines are based on a reliable upstream process with mammalian cell suspension…

Bayer opens doors at CA cell therapy plant

Bayer says the $250 million Berkeley plant will support its growing advanced therapy pipeline, including the potential launch of Parkinson’s cell therapy bemdaneprocel (BRT-DA01). In April 2021, Bayer laid down plans to build its Cell Therapy Launch Facility on its 46-acre campus in Berkeley, California at a cost of approximately $200 million. Two-and-a-half years on, and with an additional cost of $50 million, the German pharma giant has opened the 100,000 square-foot facility, bringing modular space for cell culture, viral…

Thermo Fisher ups bio capacity to 50kL at expanded Missouri site

Thermo Fisher has expanded its biologics site in St. Louis by adding two manufacturing suites.  The 58,000 square-foot unit run by CDMO (contract development and manufacturing organization) division Patheon (acquired in 2017), will support the production of biologics.  Talking to BioProcess Insider, vice president and general manager of Biologics at Thermo Fisher Scientific, Paul Jorjorian said, “The expansion is reflective of the growth we anticipate in our Biologics business, in particular the growth at our St. Louis site. The new…

A whole Lotte land: CDMO selects Songdo to build ‘mega’ plants

Lotte has signed a land purchase agreement in Songdo, Korea to build three plants with a total of 360,000 L capacity. Contract development manufacturing organization (CDMO) Lotte Biologics said in January it would invest $3 billion over the next seven years to construct three ‘mega’ plants in Korea with a production capacity of 360,000 L. Nine months later, the firm took its first steps to establishing the planned plants and signed a land purchase agreement with the Incheon Free Economic…

Talaris CGT plants bulk out NYBCe CDMO biz

New York Blood Center Enterprises (NYBCe) has acquired cell and gene therapy (CGT) facilities in Texas and Kentucky from Talaris Therapeutics. The facilities bring blood and stem cell services firm NYBCe approximately 20,000 square feet of autologous and allogeneic cell therapy development and manufacturing space in Louisville, Kentucky and 6,000 square feet of analytical and process development capacity in Houston, Texas. Both facilities have been acquired from Phase II allogeneic cell therapy developer Talaris, which earlier this year merged with…

Ins and Outs: Top-level additions at Repligen, ViroCell, Fujifilm, and Aldevron

Repligen and Aldevron appoint new presidents; ViroCell makes additions amongst its top echelon; Fujifilm hires a quality officer. Welcome to this week’s roundup brought to you by BioProcess Insider.  Repligen  Repligen, announced the appointment of Olivier Loeillot as president and COO of the company, focused on the development and production of materials used in the manufacture of biological drugs. With 20+ years of experience, Olivier previously served as the bioprocess president at Cytiva between 2018 and 2022.   CEO at Repligen,…

Rise of the recombinants: Global mammalian capacity to reach 8,400kL by 2027

Demand for mammalian biomanufacturing capacity is growing at nearly 11.5% per year and will increasingly be fed by CDMOs, says a report published ahead of CPHI Barcelona. The biomanufacturing sector is set to continue its upward trajectory, according to a report looking at supply and demand trends for mammalian capacity from BioProcess Technology Group BDO. The findings seen by this publication form part of this year’s CPHI annual report, ahead of what is the world’s largest pharma event happening in…

Seeing double: MilliporeSigma opens two mRNA manufacturing sites

MilliporeSigma claims it is the first provider to offer fully integrated mRNA services as it opens two manufacturing plants in Germany. MilliporeSigma – the life sciences division of Germany’s Merck KGaA – has opened two messenger RNA (mRNA) drug substance manufacturing facilities in Darmstadt and Hamburg, Germany. As a result, the contract development manufacturing organization (CDMO) said it is the first to offer integrated services for all stages of mRNA development, production, commercialization, and testing. “The development and manufacturing of…

LG Chem eyes manufacturing plant after securing land in Vacaville

Korean firm LG Chem is considering building its first US biomanufacturing facility after acquiring 15-acres of land from Agenus Bio in Vacaville, California. LG Chem is one of the world’s largest chemical firms but has rapidly been growing its life sciences business over the past few years. Beyond a portfolio of growth hormones, diabetes medications, and kidney cancer treatments, the firm has a widening pipeline of innovative drugs developed both inhouse and through pharma partnerships. Now the firm has signaled…

WuXi Vaccines opens China plant

Contract development manufacturing organisation (CDMO) WuXi Vaccines has inaugurated a facility in Suzhou acquired from Harbour BioMed last year. The 8,500 square-meter vaccine manufacturing site, located near Shanghai, will employ up to five hundred people. The site’s drug substance production area includes two cell culture lines and one purification line capable of scaling up production from 50 to 1,000 L, with reserved capacity for up to 2,000 L. The drug product section, meanwhile, is equipped with an automatic vial washing,…